Pain Overview

More than 100 million people suffer from chronic pain in the U.S., and millions more suffer from acute pain – more than diabetes, heart disease and cancer combined. The total annual incremental cost of health care due to pain ranges from $560 billion to $635 billion in the U.S., which combines the medical costs of pain care and the economic costs related to disability days and lost wages and productivity.1

Pain can be a symptom related to injury or sickness and can also be considered a disease itself. Chronic pain is often defined as any pain lasting more than 12 weeks2, and includes ailments such as severe headache, back pain, cancer pain and arthritic pain. Chronic pain is the most common cause of long-term disability in the U.S.3 and can cause depression, feelings of hopelessness and sleep disruption.4

Acute pain often starts suddenly and is short-term, serving as an alert to injury or illness. Acute pain often affects those undergoing surgery. With approximately 70 million surgical procedures performed in the U.S. each year5, postsurgical pain represents a significant healthcare burden. Analgesia in the surgical setting is important for patient comfort, recovery and reduction of time in the hospital. More importantly, unrelieved pain may have short and long-term, adverse effects on heart rate, blood pressure, the immune system, pulmonary function, sleep, mood and ambulation.6 Effective control of postsurgical pain may have long-term consequences such as a reduction in risk of chronic pain and mortality rates.7

Current Standard of Care for Acute, Postoperative Pain

Opioids (including hydromorphone, morphine and fentanyl) represent 79% of the volume of injectable analgesics, with non-opioids representing 21% (the majority of which, 17%, is Toradol IV, or ketorolac). In 2017, there was an 18% year over year increase in IV ketorolac use, and a 3% year over year decrease in injectable opioid use.8

Opioids have historically been a mainstay of treatment for patients with moderate-to-severe acute pain, despite the inherent risks and issues, which include dangerous side effects, increased hospitalization expenses, administrational burden and abuse and diversion liability.

Current parenteral ketorolac products for postoperative pain are only available as bolus injections (intravenous/intramuscular) and require repeating dosing to treat pain, which may result in analgesic gaps for patients. Additionally, formulating the ketorolac mixture is often risky and time-consuming for healthcare providers, and the injection can be painful for patients due to the alcohol formulation.

The Neumentum Answer

Senior couple jogging in a forest pictureNeumentum’s products aim to address shortfalls in current pain management practices by offering patients and professionals safer and more effective pain treatment options. Neumentum’s lead product candidate, NTM-001 (Ketorolac PMB – Pre-mixed Bag), represents a highly efficacious, well-established NSAID aiming to provide stable pain relief by continuous infusion for up to 24 hours. NTM-001 may reduce analgesic gaps for patients without opioids and may eliminate the need for multiple doses, ensuring patients cannot exceed the dose ceiling. Additionally, NTM-001 is an alcohol-free formulation, avoiding pain for patients upon injection. Neumentum’s product candidates may reduce institutional liability and administrative burdens, supplying convenient, safe, effective and economical medicines for patients and caregivers. Learn more about Neumentum’s products here.

Disclaimer: These are investigational new drug candidates and are not approved for any indication in any markets.